天疱疮患者血清白细胞介素-21水平：治疗前后情况

Serum IL-21 level in patients with pemphigus: Before and after treatment.

作者信息

Morsy Hanan, Zedan Hatem, Kassim Marwa, Mwafey Ibrahim M, Negm Dalia

机构信息

Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Student University Hospital, Assiut University, Assiut, Egypt.

出版信息

Dermatol Ther. 2020 Nov;33(6):e14482. doi: 10.1111/dth.14482. Epub 2020 Nov 9.

DOI:10.1111/dth.14482

PMID:33128405

Abstract

Interleukin-21 (IL-21) is believed to play a pathogenic role in the development of pemphigus. Our aim was to assess serum IL-21 levels in pemphigus patients before and after treatment. Twenty patients with pemphigus (pemphigus group) and 10 healthy controls (control group) were enrolled. Patients were assessed clinically using the Pemphigus Disease Area Index (PDAI) at presentation and 2 months after treatment. Serum samples were collected to measure serum IL-21 levels by enzyme-linked immunosorbent assay (ELISA), at presentation and after 2 months of treatment. The mean age of the participants was 41.9 ± 13.5 years (7 men and 13 women). The PDAI score at presentation was 37.35 ± 14.206, which decreased significantly after treatment to 11.70 ± 6.729 (P-value <.001). On the other hand, serum IL-21 levels increased after treatment (589.03 ± 131.86 ng/L at first presentation vs 627.10 ± 304.05 ng/L after treatment: P-value .444). No significant correlation was found between the PDAI severity scores and serum IL-21 levels at the first presentation or 2 months after treatment.

摘要

白细胞介素-21（IL-21）被认为在天疱疮的发病过程中起致病作用。我们的目的是评估天疱疮患者治疗前后的血清IL-21水平。招募了20例天疱疮患者（天疱疮组）和10名健康对照者（对照组）。在就诊时和治疗2个月后，使用天疱疮疾病面积指数（PDAI）对患者进行临床评估。在就诊时和治疗2个月后，采集血清样本，通过酶联免疫吸附测定（ELISA）测量血清IL-21水平。参与者的平均年龄为41.9±13.5岁（7名男性和13名女性）。就诊时的PDAI评分为37.35±14.206，治疗后显著降低至11.70±6.729（P值<.001）。另一方面，治疗后血清IL-21水平升高（首次就诊时为589.03±131.86 ng/L，治疗后为627.10±304.05 ng/L：P值.444）。在首次就诊时或治疗2个月后，未发现PDAI严重程度评分与血清IL-21水平之间存在显著相关性。